Dual inhibition of EGFR and AURKA could offer synergistic mechanisms to overcome resistance and suppress tumours such as SCCHN and NSCLC where redundancy in EGFR and AURKA signaling is observed.6–9. The gene discussed is AURKA; the disease is head and neck squamous cell carcinoma.